Physiology Regarding Apnoeic Oxygenation During Nasal Cannula Therapy at Different Flow Rates

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

125 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-25

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study compares under controlled conditions if different flow rates affect apnoea time after induction of anaesthesia and how CO2 clearance is influenced. Furthermore, this study enables to quantify the effects of increased pCO2 on vital parameters (e.g. blood pressure, cardiac output, cerebral perfusion, etc.) The investigators will enroll patients undergoing elective surgery at the University Hospital of Bern, Switzerland.

Once anesthesia has been induced, apnoea will set it. During this period, the investigators will compare different methods of apnoeic oxygenation for a maximum of 15 or 30 minutes.

Before discharge, an interview will be conducted, assessing complications and patient satisfaction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Positive Airway Pressure Under Apnoeic Oxygenation With Different Flow Rates in Nasal Cannula Therapy

NCT03738722

Apnoeic Oxygenation

COMPLETED NA

Oxygenation by 100% Oxygen Via High Flow Nasal Cannula in Surgical Patients

NCT02706431

Anaesthesia, General Anesthesia, Intravenous Ventilation

COMPLETED NA

Effects on Experimental Dyspnea of High Flow Nasal Cannula

NCT03469037

Dyspnea Healthy Volunteers

COMPLETED NA

Apnoeic Oxygenation by Nasal Cannula During Airway Management in Children Undergoing General Anaesthesia.

NCT03271827

Apnoeic Oxygenation

COMPLETED NA

Correlation of Peak Tidal Inspiratory Flow Measured Before and After Extubation in Adult Patients With Hypoxemia

NCT04971148

Hypoxemic Respiratory Failure

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eligible, consenting adults will be prepared for general anaesthesia in the usual way consisting of ECG, pulse-oximetry, NarcotrendTM, a venous cannula and an arterial line for continuous blood pressure monitoring. They will receive additional monitoring such as transcutaneous measurement of pCO2 and O2, NIRS, and thoracic electrical impedance tomography (EIT, PulmoVista® 500, Draeger, Luebeck, Germany).

Normal pre-oxygenation (until etO2 is \> 90% or time \> 3 minutes) will occur. Anaesthesia will be started (= "induction") using Propofol and Fentanyl, using NarcotrendTM to measure depth of anaesthesia. All patients will receive a standard dose of neuromuscular blockage to facilitate airway management and total intravenous anaesthesia will be installed. Using the train of four measurement (TOF) full neuromuscular blockage with Rocuronium will be confirmed every 30 seconds. If necessary, additional dosage of neuromuscular blockage will be administered.

After administration of Rocuronium, possibility of mask ventilation will be confirmed and the sealed envelope with the randomization will then be opened. As a study intervention, the assigned method (HFNCT 70 l/min with either jaw thrust or laryngoscopy, or 10 l/min or 2l/min with the standard nasal canula, or 0.25l/min delivery of oxgen via a tracheal tube) will be installed and mask ventilation discontinued starting the apnoea period. Nasopharyngoscopy (EF-N slim, Acutronic, Hirzel, Switzerland) will confirm upper airway patency. Blood gas analysis will be conducted: baseline awake, start of apnoea, first minute after apnoea start, and every 2 minutes thereafter with a maximum of 75ml 150 ml in total. Other measurements (ECG, pulse-oximetry, blood pressure, NIRS, thoracic EIT, NarcotrendTM, PtcO2, PtcCO2) will be measured continuously over the study period The study intervention will end when one of the following criteria (study end-points) is met: SpO2 \<92%, PtcCO2 \> 100 mmHg or time \> 30 minutes.

When any of the end points is reached, patient-centred standard anaesthesia care will be continued, as planned for the case.

A post-operative interview will be conducted before discharge to evaluate injuries during airway management (bleeding, sore throat, hoarseness), pain, postoperative nausea and vomiting.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Apnoeic Oxygenation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

single centre, prospective, randomized-controlled trial

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Patients will be blinded as they receive general anesthesia. Care providers cannot be blinded, due to obvious differences in set-up of the different interventions.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

These patients will receive HFNCT with oxygen 70l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, continuous videolaryngoscopy will be performed.

Group Type ACTIVE_COMPARATOR

Oxygen 70l/min

Intervention Type DRUG

HFNCT will be provided using OptiFlow by Fisher\&Paykel.

Videolaryngoscopy

Intervention Type PROCEDURE

Continuous

High flow

These patients will receive HFNCT with oxygen 70l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.

Group Type EXPERIMENTAL

Oxygen 70l/min

Intervention Type DRUG

HFNCT will be provided using OptiFlow by Fisher\&Paykel.

Jaw thrust

Intervention Type PROCEDURE

Continuous

medium flow

These patients will receive oxygen 10l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.

Group Type EXPERIMENTAL

Oxygen 10 l/min

Intervention Type DRUG

Medium flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.

Jaw thrust

Intervention Type PROCEDURE

Continuous

low flow

These patients will receive oxygen 2l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.

Group Type EXPERIMENTAL

Oxygen 2l/min

Intervention Type DRUG

Low flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.

Jaw thrust

Intervention Type PROCEDURE

Continuous

minimal flow

These patients will receive a standard tracheal tubes after induction of general anesthesia, with 100% Oxygen and Minimum-flow 0.25l/min. The measurement period is 15 or 30 minutes.

Group Type EXPERIMENTAL

oxygen 0.25l/min

Intervention Type DRUG

0.25l/min of oxygen via an endotracheal tube

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxygen 70l/min

HFNCT will be provided using OptiFlow by Fisher\&Paykel.

Intervention Type DRUG

Oxygen 10 l/min

Medium flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.

Intervention Type DRUG

Oxygen 2l/min

Low flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.

Intervention Type DRUG

Jaw thrust

Continuous

Intervention Type PROCEDURE

Videolaryngoscopy

Continuous

Intervention Type PROCEDURE

oxygen 0.25l/min

0.25l/min of oxygen via an endotracheal tube

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

high flow medium flow low flow minimal flow

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \> 18 years
* Written informed consent
* Undergoing elective surgery
* Requiring general anesthesia

Exclusion Criteria

* Any Indication for fibre optic intubation
* Expected impossible mask ventilation
* Known coronary heart disease
* Known heart failure, NYHA classification ≥ 2
* Therapy including β-receptor antagonists
* Arrhythmias in need of anti-arrhythmic therapy (e.g. implanted cardio defibrillator)
* Peripheral occlusive arterial disease, Fontaine ≥ 2b
* Known stenosis of the (common or internal) carotid or vertebral arteries
* BMI \> 35kg/m2 and BMI \< 16kg/m2
* Hyperkalaemia (K \> 5.5 mmol/l)
* Known COPD Gold classification ≥ 2
* Known pulmonary arterial hypertension, systolic \> 35mmHg
* Known obstructive sleep apnoea syndrome in need of therapy
* High risk of aspiration (requiring rapid sequence induction intubation)
* Increased intracranial pressure
* Intracranial surgery
* Limited knowledge of German language
* Absent power of judgement
* Anaemia, Hb \< 100 g/l
* Pregnancy (pregnancy test in all female patients)
* Neuromuscular disorder
* Known or suspected cervical spine instability
* Nasal obstruction, impossibility of nasal ventilation (both sides patent)
* Allergies or contra-indications to one or more of the used anaesthesia agents

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No